What Is Lp Testing

Lp(a) testing is a blood test that quantifies lipoprotein(a), a lipoprotein particle composed of an LDL-like core bound to apolipoprotein(a). Lp(a) levels are more than 90 percent determined by genetics, making this one of the strongest inherited risk factors for atherosclerotic cardiovascular disease. The test identifies individuals carrying elevated levels who may benefit from more aggressive management of other modifiable cardiovascular risk factors.

Cardiovascular disease remains the leading cause of death globally, and standard lipid panels measure LDL cholesterol, HDL cholesterol, and triglycerides without distinguishing Lp(a) from the broader LDL pool. A person can have a seemingly normal lipid profile yet carry highly elevated Lp(a), which independently accelerates plaque formation, promotes blood clotting, and drives inflammation within arterial walls. This hidden risk is estimated to affect roughly one in five people at levels associated with meaningfully increased cardiovascular hazard.

Because Lp(a) is genetically determined and largely unchangeable by lifestyle, knowing one's level shifts the strategic calculus for longevity. An elevated result does not guarantee disease, but it reframes how aggressively other risk factors (blood pressure, LDL particle count, metabolic health, inflammation) should be managed. For individuals pursuing cardiovascular longevity, Lp(a) testing fills a critical blind spot that conventional screening misses entirely.

Lipoprotein(a) is assembled in the liver when apolipoprotein(a), encoded by the LPA gene, covalently bonds to an apolipoprotein B-100 molecule on an LDL particle. The resulting complex circulates in the bloodstream and participates in atherogenesis through multiple mechanisms. It infiltrates the arterial intima like standard LDL, but its apolipoprotein(a) tail has structural homology with plasminogen, the precursor to the body's primary clot-dissolving enzyme. This molecular mimicry allows Lp(a) to compete with plasminogen for binding sites on fibrin clots, effectively inhibiting fibrinolysis and tilting the balance toward thrombosis.

Within the arterial wall, Lp(a) carries oxidized phospholipids that activate inflammatory signaling cascades, recruit monocytes, and promote foam cell formation. These processes accelerate plaque development beyond what LDL cholesterol alone would produce. The oxidized phospholipid cargo also contributes to calcification of the aortic valve, explaining the epidemiological association between elevated Lp(a) and aortic stenosis.

The test itself is performed on a standard blood draw. Laboratories report Lp(a) in either mass units (milligrams per deciliter) or molar units (nanomoles per liter). Because apolipoprotein(a) varies in size due to a variable number of kringle IV type 2 repeats, mass-based assays can be misleading; molar concentration (nmol/L) is considered more accurate and is preferred by most cardiovascular risk assessment guidelines. Direct conversion between the two units is unreliable, and results should be interpreted in whichever unit the assay was designed to report.

The Lp(a) test measures the concentration of lipoprotein(a) particles circulating in the blood. Each Lp(a) particle consists of a single LDL-like core, containing apolipoprotein B-100, linked by a disulfide bond to apolipoprotein(a). It is this apolipoprotein(a) component that distinguishes Lp(a) from standard LDL and confers its unique prothrombotic and proinflammatory properties.

The test does not assess LDL cholesterol, HDL cholesterol, or triglycerides; it is a separate, specialized assay. Importantly, most standard lipid panels do not include Lp(a), meaning a person could undergo routine cholesterol screening for decades without this particle ever being measured. Laboratories may use turbidimetric, nephelometric, or ELISA-based methods. Assays calibrated in nmol/L, which count particle number regardless of apolipoprotein(a) isoform size, are considered more reliable than those reporting in mg/dL, which measure mass and can overestimate or underestimate risk depending on isoform size.

No special preparation is needed for an Lp(a) blood draw. Fasting is not required because Lp(a) concentrations are minimally influenced by recent meals. If the test is ordered alongside a standard fasting lipid panel, the fasting requirement applies to the other lipid measurements, not to Lp(a) itself.

Exercise, acute illness, and certain medications can temporarily affect many blood biomarkers, but Lp(a) levels are remarkably stable and are unlikely to shift meaningfully due to short-term factors. The main preparation step is to confirm with the laboratory or ordering clinician that the assay will report in nmol/L, as this unit provides the most accurate risk stratification across individuals with different apolipoprotein(a) isoform sizes.

Lp(a) results are typically reported in one of two units: nmol/L (nanomoles per liter) or mg/dL (milligrams per deciliter). When reported in nmol/L, levels below 75 nmol/L are generally considered within a lower-risk range, while levels above 125 nmol/L indicate meaningfully elevated cardiovascular risk. In mg/dL, thresholds are often cited as below 30 mg/dL (desirable) and above 50 mg/dL (elevated), though these thresholds are less precise due to isoform size variability.

Risk is continuous rather than binary. There is no sharp cutoff below which Lp(a) carries zero risk and above which disease is certain. Higher levels are associated with progressively greater risk, particularly when other cardiovascular risk factors are present. Context matters: an elevated Lp(a) in someone with excellent metabolic health, low ApoB, and no coronary calcium carries a different prognostic weight than the same level in someone with insulin resistance and existing plaque.

Because no widely approved Lp(a)-lowering therapy currently exists, an elevated result typically leads to more aggressive management of other modifiable risk factors. This may include tighter LDL or ApoB targets, closer monitoring with coronary calcium scoring or CT angiography, and optimization of blood pressure, metabolic health, and inflammation. Some clinicians consider low-dose aspirin in high-risk individuals, though this decision involves weighing bleeding risk and should be individualized.

Because Lp(a) levels are more than 90 percent genetically determined, they remain remarkably stable across the lifespan. A single measurement is generally sufficient to establish an individual's risk category. Repeat testing is rarely necessary unless a patient begins a therapy specifically designed to lower Lp(a), such as an antisense oligonucleotide or small interfering RNA (should these receive regulatory approval), or if there is reason to question the initial result due to assay methodology concerns.

Some transient fluctuations in Lp(a) can occur during acute inflammatory states, after major surgery, or in the setting of kidney or liver disease, as these conditions alter hepatic lipoprotein metabolism. If the initial test was drawn during such a period, a confirmatory measurement under baseline conditions is reasonable. Otherwise, one well-timed test provides durable, lifelong information.

The epidemiological evidence linking elevated Lp(a) to cardiovascular disease is substantial. Large population-based studies, Mendelian randomization analyses, and genome-wide association studies consistently show that genetically determined high Lp(a) levels are associated with increased risk of myocardial infarction, ischemic stroke, aortic valve stenosis, and peripheral arterial disease. These genetic studies are particularly informative because they eliminate confounding: the lifelong exposure to elevated Lp(a) acts as a natural experiment that isolates its causal contribution to disease.

The therapeutic landscape is less settled. Niacin reduces Lp(a) modestly but has not demonstrated cardiovascular benefit in large outcome trials when added to statin therapy, raising questions about whether its Lp(a) reduction translates into clinical protection. PCSK9 inhibitors lower Lp(a) as a secondary effect, and post-hoc analyses of major trials suggest that patients with higher baseline Lp(a) derive greater benefit, though these analyses were not pre-specified. Antisense oligonucleotides and small interfering RNA therapies targeting hepatic Lp(a) production have shown reductions of 80 percent or more in phase 2 trials, but cardiovascular outcome trials are ongoing and results are not yet available. Until these trials report, the clinical question of whether lowering Lp(a) directly reduces events remains open.

Lp(a) testing itself carries no meaningful risk beyond a standard blood draw. The primary consideration is psychological: learning that one carries a genetically fixed, currently difficult-to-treat risk factor can cause anxiety, particularly given the limited pharmacological options available. There is also a measurement challenge, as different assay methodologies and reporting units can lead to confusion if results are compared across laboratories. Working with a clinician familiar with advanced lipid testing helps ensure the result is interpreted correctly and integrated into a proportionate, evidence-based risk management strategy.